Seasonal variation of relapse rate in multiple sclerosis is latitude dependent

Annals of Neurology

Volumn 76, Issue 6, 2014, Pages 880-890

  Spelman, Tim ^a   Gray, Orla ^b   Trojano, Maria ^c   Petersen, Thor ^d   Izquierdo, Guillermo ^e,f   Hupperts, Raymond ^g   Bergamaschi, Roberto ^h   Duquette, Pierre ⁱ   Grammond, Pierre ^j   Giuliani, Giorgio ^k   Boz, Cavit ^l   Verheul, Freek ^m   Oreja Guevara, Celia ⁿ   Barnett, Michael ^o   Gr'Maison, Francois ^p   Rio, Maria Edite ^q   Lechner Scott, Jeannette ^r   Van Pesch, Vincent ^s   Bolanos, Ricardo Fernez ^t   Flechter, Shlomo ^u   Braber Moerl, Leontien Den ^v   Iuliano, Gerardo ^w   Amato, Maria Pia ^x   Slee, Mark ^y   Cristiano, Edgardo ^z   Saladino, Maria Laura ^aa   Paine, Mark ^ab   Vella, Norbert ^ac   Kasa, Krisztian ^ad   Deri, Norma ^ae   Herbert, Joseph ^af   Moore, Fraser ^ag   Petkovska Boskova, Tatjana ^ah   Alroughani, Raed ^ai   Savino, Aldo ^aj   Shaw, Cameron ^ak   Vucic, Steve ^al   Santiago, Vetere ^am   Bacile, Elizabeth Alejra ^an   Skromne, Eli ^ao   Poehlau, Dieter ^ap   Cabrera Gomez, Jose Antonio ^aq   Lucas, Robyn ^ar   Butzkueven, Helmut ^a,as   more..

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b CRAIGAVON AREA HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BARI   (Italy)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^f UNIVERSITY OF CHIETI   (Italy)

^g Sittard Geleen Heerlen   (Netherlands)

^h C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

ⁱ NOTRE DAME HOSPITAL   (Canada)

^j Chaudière Appalache Physical Disability Rehabilitation Center   (Canada)

^k Macerata Hospital   (Italy)

^l KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^m Green Heart Hospital   (Netherlands)

ⁿ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^o UNIVERSITY OF SYDNEY   (Australia)

^p HÔPITAL CHARLES LEMOYNE   (Canada)

^q St John Center Hospital   (Portugal)

^r JOHN HUNTER HOSPITAL   (Australia)

^s Louvain Catholic University   (Belgium)

^t HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^u ASSAF HAROFEH MEDICAL CENTER   (Israel)

^v Francicus Ziekenhuis   (Netherlands)

^w Salerno Hospital   (Italy)

^x UNIVERSITY OF FLORENCE   (Italy)

^y FLINDERS UNIVERSITY   (Australia)

^z HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^aa Buenos Aires Institute of Neurosciences ^*  (Argentina)

^ab ST VINCENT S HOSPITAL   (Australia)

^ac MATER DEI HOSPITAL   (Malta)

^ad Jahn Ferenc Del Pesti korhaz Budapest   (Hungary)

^ae HOSPITAL JUAN A FERNÁNDEZ   (Argentina)

^af NYU HOSPITAL FOR JOINT DISEASES   (United States)

^ag MCGILL UNIVERSITY   (Canada)

^ah Institute for Public Health   (Macedonia)

^ai AL AMIRI HOSPITAL   (Kuwait)

^aj Private Practice   (Argentina)

^ak GEELONG HOSPITAL   (Australia)

^al WESTMEAD HOSPITAL   (Australia)

^am Hospital Interzonal General de Agudos de La Plata   (Argentina)

^an Cordoba Neurosciences Institute ^*  (Argentina)

^ao Hospital Angeles Mexico   (Mexico)

^ap Multiple Sclerosis Center Camillus Hospital   (Germany)

^aq CENTRO INTERNACIONAL DE RESTAURACIÓN NEUROLÓGICA CIREN   (Cuba)

^ar The Australian National University   (Australia)

^as UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AUTUMN; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; LATITUDE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); MULTIPLE SCLEROSIS; NORTHERN HEMISPHERE; RECURRENCE RISK; REGISTER; SEASONAL VARIATION; SENSITIVITY ANALYSIS; SOUTHERN HEMISPHERE; SPRING; ULTRAVIOLET RADIATION; CLINICAL TRIAL; FACTUAL DATABASE; INTERNATIONAL COOPERATION; LONGITUDINAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROSPECTIVE STUDY; RECURRENT DISEASE; SEASON; SUNLIGHT; TRENDS; YOUNG ADULT;

ADULT; DATABASES, FACTUAL; FEMALE; HUMANS; INTERNATIONALITY; LONGITUDINAL STUDIES; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROSPECTIVE STUDIES; RECURRENCE; REGISTRIES; SEASONS; SUNLIGHT; ULTRAVIOLET RAYS; YOUNG ADULT;

EID: 84913526146     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24287     Document Type: Article

References (67)

1. Simpson S Jr, Blizzard L, Otahal P, et al. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry 2011;82:1132-1141.
2. Risco J, Maldonado H, Luna L, et al. Latitudinal prevalence gradient of multiple sclerosis in Latin America. Mult Scler 2011;17: 1055-1059.
3. Hollingworth S, Walker K, Page A, Eadie M. Pharmacoepidemiology and the Australian regional prevalence of multiple sclerosis. Mult Scler 2013;19:1712-1716.
4. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 2007;61:504-513.
5. Simpson S Jr, Taylor B, Blizzard L, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010;68:193-203.
6. Lucas RM, Ponsonby AL, Dear K, et al. Vitamin D status: multifactorial contribution of environment, genes and other factors in healthy Australian adults across a latitude gradient. J Steroid Biochem Mol Biol 2013;136:300-308.
7. Kampman MT, Brustad M. Vitamin D. A candidate for the environmental effect in multiple sclerosis-observations from Norway. Neuroepidemiology 2008;30:140-146.
8. Mowry EM, Waubant E, McCulloch CE, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 2012;72:234-240.
9. Jin Y, de Pedro-Cuesta J, Soderstrom M, et al. Seasonal patterns in optic neuritis and multiple sclerosis: a meta-analysis. J Neurol Sci 2000;181:56-64.
10. Bamford CR, Sibley WA, Thies C. Seasonal variation of multiple sclerosis exacerbations in Arizona. Neurology 1983;33:697-701.
11. Bisgard C. Seasonal variation in disseminated sclerosis [in Danish]. Ugeskr Laeger 1990;152:1160-1161.
12. Callaghan TS. Multiple sclerosis and sinusitis. Lancet 1986;2:160-161.
13. Gay D, Dick G, Upton G. Multiple sclerosis associated with sinusitis: a case-controlled study in general practice. Lancet 1986;1: 815-819.
14. Goodkin DE, Hertsgaard D. Seasonal variation of multiple sclerosis exacerbations in North Dakota. Arch Neurol 1989;46:1015-1018.
15. Hopkins CE, Swank RL. Multiple sclerosis and the local weather. Arch Neurol 1955;74:203-207.
16. O'Reilly MA, O'Reilly PM. Temporal influences on relapses of multiple sclerosis. Eur Neurol 1991;31:391-395.
17. Schapira K. The seasonal incidence of onset and exacerbations in multiple sclerosis. J Neurol Neurosurg Psychiatry 1959;22:285-286.
18. Sibley WA, Foley JM. Seasonal variation in multiple sclerosis and retrobulbar neuritis in northeastern Ohio. Trans Am Neurol Assoc 1965;90:295-297.
19. Sosa Enriguez M, Betancor Leon P, Rosas C, et al. Multiple sclerosis in the province of Las Palmas [in Spanish]. Arch Neurobiol (Madr) 1983;46:161-166.
20. Abella-Corral J, Prieto JM, Dapena-Bolano D, et al. Seasonal variations in the outbreaks in patients with multiple sclerosis. Rev Neurol 2005;40:394-396.
21. Ogawa G, Mochizuki H, Kanzaki M, et al. Seasonal variation of multiple sclerosis exacerbations in Japan. Neurol Sci 2004;24:417-419.
22. Koziol JA, Feng AC. Seasonal variations in exacerbations and MRI parameters in relapsing-remitting multiple sclerosis. Neuroepidemiology 2004;23:217-223.
23. Butzkueven H, Chapman J, Cristiano E, et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler 2006;12:769-774.
24. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
25. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
26. NASA GSFC TOMS EPTOMS: Total ozone mapping spectrometer on board the Earth Probe spacecraft. Available at: http://iridl. ldeo.columbia.edu/SOURCES/.NASA/.GSFC/.TOMS. Accessed October 1, 2013.
27. Stolwijk AM, Straatman H, Zielhuis GA. Studying seasonality by using sine and cosine functions in regression analysis. J Epidemiol Community Health 1999;53:235-238.
28. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-281.
29. Holick MF. Vitamin D: evolutionary, physiological and health perspectives. Curr Drug Targets 2011;12:4-18.
30. Hagenau T, Vest R, Gissel TN, et al. Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: an ecologic meta-regression analysis. Osteoporos Int 2009;20:133-140.
31. Pierrot-Deseilligny C, Souberbielle JC. Widespread vitamin D insufficiency: a new challenge for primary prevention with particular reference to multiple sclerosis. Presse Med 2011;40:349-356.
32. Shoben AB, Kestenbaum B, Levin G, et al. Seasonal variation in 25-hydroxyvitamin D concentrations in the cardiovascular health study. Am J Epidemiol 2011;174:1363-1372.
33. Mowry EM, Krupp LB, Milazzo M, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010;67:618-624.
34. Pierrot-Deseilligny C, Rivaud-Pechoux S, Clerson P, et al. Relationship between 25-OD-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation. Ther Adv Neurol Disord 2012;5:187-198.
35. Auer DP, Schumann EM, Kumpfel T, et al. Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2000;47:276-277.
36. Mowry EM, Waubant E, McCulloch CE, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 2012;72:234-240.
37. Zivadinov R, Treu CN, Weinstock-Guttman B, et al. Interdependence and contributions of sun exposure and Vitamin D to MRI measures in multiple sclerosis. J Neurol Neurosurg Psychiatry 2013;84:1075-1081.
38. Eccles R. An explanation for the seasonality of acute upper respiratory tract viral infections. Acta Otolaryngol 2002;122:183-191.
39. London WP, Yorke JA. Recurrent outbreaks of measles, chickenpox and mumps. I. Seasonal variation in contact rates. Am J Epidemiol 1973;98:453-468.
40. Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001;127:305-314.
41. Sabetta JR, DePetrillo P, Cipriani RJ, et al. Serum 25-hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults. PLoS One 2010;5:e11088.
42. Sibley W, Bamford C, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985;325:1313-1315.
43. Andersen O, Lygner PE, Bergstr €om T, et al. Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J Neurol 1993;240:417-422.
44. Panitch HS. Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 1994;36(suppl):S25-S28.
45. Edwards S, Zvartau M, Clarke H, et al. Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:736-741.
46. Smith KJ, McDonald WI. The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci 1999;354:1649-1673.
47. Buljevac D, Flach HZ, Hop WC, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002;125:952-960.
48. Hart PH, Gorman S, Finlay-Jones JJ. Modulation of the immune system by UV radiation: more than just the effects of vitamin D? Nat Rev Immunol 2011;11:584-596.
49. Lemire JM, Archer DC, Beck L, Spiegelberg HL. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr 1995;125(6 suppl):1704S-1708S.
50. Tsoukas CD, Watry D, Escobar SS, et al. Inhibition of interleukin-1 production by 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab 1989;69:127-133.
51. Lemire JM. Immunomodulatory actions of 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 1995;53:599-602.
52. van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 2005;97:93-101.
53. Tsoukas CD, Provvedini DM, Manolagas SC. 1,25-Dihydroxyvitamin D3: a novel immunoregulatory hormone. Science 1984;224: 1438-1440.
54. Smolders J, Menheere P, Kessels A, et al. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008;14:1220-1224.
55. Provvedini DM, Manolagas SC. 1 alpha,25-Dihydroxyvitamin D3 receptor distribution and effects in subpopulations of normal human T lymphocytes. J Clin Endocrinol Metab 1989;68:774-779.
56. Provvedini DM, Tsoukas CD, Deftos LJ, et al. 1 alpha,25-Dihydroxyvitamin D3-binding macromolecules in human B lymphocytes: effects on immunoglobulin production. J Immunol 1986;136: 2734-2740.
57. Lemire JM, Archer DC. 1,25-Dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991;87:1103-1107.
58. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 1996;93: 7861-7864.
59. Pedersen LB, Nashold FE, Spach KM, et al. 1,25-Dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J Neurosci Res 2007;85:2480-2490.
60. Ng RL, Bisley JL, Gorman S, et al. Ultraviolet irradiation of mice reduces the competency of bone marrow-derived CD11c 1 cells via an indomethacin-inhibitable pathway. J Immunol 2010;185: 7207-7215.
61. Norval M, Halliday GM. The consequences of UV-induced immunosuppression for human health. Photochem Photobiol 2011;87: 965-977.
62. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol 2012;188:21-28.
63. Norval M, Woods GM. UV-induced immunosuppression and the efficacy of vaccination. Photochem Photobiol Sci 2011;10:1267-1274.
64. Soilu-Hanninen M, Å; ivo J, Lindstrom BM, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferonß-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83:565-571.
65. Derakhshandi H, Etemadifar M, Feizi A, et al. Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial. Acta Neurol Belg 2013;113: 257-263.
66. Stein MS, Liu Y, Gray OM, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 2011;77:1611-1618.
67. Smolders J, Hupperts R, Barkhof F, et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferonß-1a: a phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci 2011;311:44-49